TMA-6

The official Turkish Narkotik 2014 report reproduces Annex 2 to Decision No. 2013/5742 and expressly names TMA-6 at item 58. The latest official Turkish Drug Report (2025) identifies Law No. 2313 and TCK Articles 188, 190 and 191 as the principal framework; it describes the TUBIM Early Warning System process for bringing encountered or risked NPS under Law No. 2313, states that generic classification began in 2015, and reports 1,078 NPS brought under the law through 31 July 2025. The current official Ministry of Justice TCK publication states that unauthorized manufacture, import or export is punishable under Article 188(1) by 20–30 years' imprisonment and 2,000–20,000 days' judicial fine; domestic sale, offer, giving, dispatch, transport, storage, purchase, acceptance or possession is covered by Article 188(3) with at least 10 years' imprisonment and 1,000–20,000 days' judicial fine. Article 188(4)(a) provides a half increase when the offense involves amphetamine or its derivatives; because PubChem identifies TMA-6 as 2,4,6-trimethoxyamphetamine, that statutory category appears textually relevant to Article 188 conduct, subject to the charging court's application. Article 191 separately covers purchase, acceptance, possession for use or use with 2–5 years' imprisonment, a five-year public-prosecution postponement, at least one year of supervision, possible treatment and testing. These provisions contain statutory authorization and procedure qualifications; not every handling circumstance is unqualifiedly prohibited.

Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016.⁴ Production and import with intent to distribute, administration to others, and trading are criminally punishable offenses.⁵ Possession is prohibited but does not carry criminal penalties.⁵

TMA-6 is not explicitly scheduled by name, but the current binding BetmVV-EDI Annex 6 Verzeichnis e no. 315 generic Phenylalkylamine rule covers the TMA-6 structure (alpha-methylphenethylamine with phenyl methoxy substituents and unsubstituted amino nitrogen). Industrial and scientific use is expressly exempted by no. 315; private use is expressly not exempted. Swissmedic's public presumed-effect list is non-exhaustive and not binding. Article 19 of the official BetmG consolidation standing 1 September 2023 sets out penalties that apply conditionally; Swissmedic's 13 March 2026 announcement confirms that substances subject to the BetmG remain subject to its criminal penalties.